Finoriq research workspace
Arcutis Biotherapeutics, Inc. (ARQT) Institutional Holdings & 13F Ownership
Arcutis Biotherapeutics, Inc. also develops ZORYVE foam seborrheic dermatitis, and scalp. Review ARQT institutional holders, 13F ownership, and position changes on Finoriq.
Company Snapshot
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
- Company
- Arcutis Biotherapeutics, Inc. (ARQT)
- Ticker
- ARQT
- Market Cap
- $3.5B
- Latest Price
- $27.76
- Industry
- Biotech & Pharma
Arcutis Biotherapeutics, Inc. (ARQT) Top Institutional Holders
Top current 13F holders indexed for Arcutis Biotherapeutics, Inc. (ARQT). Latest period 2026-03-31.
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.